-transparent.png){kind=logo}
About 100 derivatives of human recombinant granulocyte colony-stimulating factor (rhG-CSF) were created by various gene-mutagenic techniques, and KW-2228, in which amino acids were replaced at five positions of N-terminal region of intact rhG-CSF, was picked up and evaluated for its biologic and physicochemical properties in comparison with intact rhG-CSF. KW-2228 showed two to four times higher specific activity than that of intact rhG-CSF in mouse and/or human bone marrow progenitor cells by colony-forming unit assay in soft agar, and by cell-proliferation assay in liquid culture. KW-2228 showed a potency to increase peripheral neutrophil counts when it was administered to normal C3H/He mice by single intravenous injection. Increase of total leukocyte count and neutrophils was observed, with peak level at 8 to 12 hours at low doses (0.5 to 1.0 micrograms/mouse), and the highest level was maintained for 24 to 30 hours at high doses (5 to 10 micrograms/mouse). The granulopoietic effect of KW-2228 was examined by several doses of single course (once daily for 10 days) or multiple courses (twice daily injection for 5 days followed by cessation for 9 days on one cycle, 3 cycles in total) of treatment. KW-2228 showed higher activity than that of rhG-CSF, especially at sub-optimal doses of multiple courses of treatment. Furthermore, KW-2228 was found to be more stable physicochemically and biologically than intact rhG-CSF, especially under thermal conditions at 56 degrees C and in the human plasma at 37 degrees C, suggesting a protease resistancy. Pharmacokinetic study showed that plasma concentration of KW-2228 assayed for its bioactivity maintained a higher level than that of intact rhG-CSF for 60 minutes after intravenous injection of this protein to normal mice. Those results suggest that KW-2228 might show a superior in vivo hematopoietic effect to intact rhG-CSF due to its high specific activity to progenitor cells, and also due to its improved physicochemical, biologic, and pharmacokinetic stability in host animals.
M Okabe, and
M Asano, and
T Kuga, and
Y Komatsu, and
M Yamasaki, and
Y Yokoo, and
S Itoh, and
M Morimoto, and
T Oka
May 1990,
Blood,
M Okabe, and
M Asano, and
T Kuga, and
Y Komatsu, and
M Yamasaki, and
Y Yokoo, and
S Itoh, and
M Morimoto, and
T Oka
February 1995,
Journal of neuroimmunology,
M Okabe, and
M Asano, and
T Kuga, and
Y Komatsu, and
M Yamasaki, and
Y Yokoo, and
S Itoh, and
M Morimoto, and
T Oka
March 1991,
Blood,
M Okabe, and
M Asano, and
T Kuga, and
Y Komatsu, and
M Yamasaki, and
Y Yokoo, and
S Itoh, and
M Morimoto, and
T Oka
January 1987,
Blood cells,
M Okabe, and
M Asano, and
T Kuga, and
Y Komatsu, and
M Yamasaki, and
Y Yokoo, and
S Itoh, and
M Morimoto, and
T Oka
January 2001,
Eksperimental'naia i klinicheskaia farmakologiia,
M Okabe, and
M Asano, and
T Kuga, and
Y Komatsu, and
M Yamasaki, and
Y Yokoo, and
S Itoh, and
M Morimoto, and
T Oka
March 1987,
Blut,
M Okabe, and
M Asano, and
T Kuga, and
Y Komatsu, and
M Yamasaki, and
Y Yokoo, and
S Itoh, and
M Morimoto, and
T Oka
November 1996,
Annals of hematology,
M Okabe, and
M Asano, and
T Kuga, and
Y Komatsu, and
M Yamasaki, and
Y Yokoo, and
S Itoh, and
M Morimoto, and
T Oka
April 1993,
Blood,
M Okabe, and
M Asano, and
T Kuga, and
Y Komatsu, and
M Yamasaki, and
Y Yokoo, and
S Itoh, and
M Morimoto, and
T Oka
August 1989,
Experimental hematology,
M Okabe, and
M Asano, and
T Kuga, and
Y Komatsu, and
M Yamasaki, and
Y Yokoo, and
S Itoh, and
M Morimoto, and
T Oka
September 1986,
Japanese journal of cancer research : Gann,
